TTR and amyloidosis: Revusiran was in development as a potential treatment for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis), a rare, life-threatening, autosomal dominant multi-systemic disease caused by mutations in the TTR gene [9].